{"id":64,"date":"2025-01-07T03:43:10","date_gmt":"2025-01-07T08:43:10","guid":{"rendered":"https:\/\/www.smpro.es\/clientes\/saned\/Landing_BristolMyers\/?page_id=64"},"modified":"2025-02-25T04:34:01","modified_gmt":"2025-02-25T09:34:01","slug":"landing-bristol-myers-articulos","status":"publish","type":"page","link":"https:\/\/clientes2.smpro.es\/clientes\/saned\/Landing_BristolMyers_OK\/landing-bristol-myers-articulos\/","title":{"rendered":"Landing Bristol Myers &#8211; Art\u00edculos"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"64\" class=\"elementor elementor-64\">\n\t\t\t\t<div class=\"elementor-element elementor-element-24a38f6 e-grid e-con-full e-con e-parent\" data-id=\"24a38f6\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-14173e9 elementor-widget elementor-widget-image\" data-id=\"14173e9\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"800\" height=\"110\" src=\"https:\/\/clientes2.smpro.es\/clientes\/saned\/Landing_BristolMyers_OK\/wp-content\/uploads\/2024\/12\/Logo-BMS-ok-1024x141.jpg\" class=\"attachment-large size-large wp-image-17\" alt=\"\" srcset=\"https:\/\/clientes2.smpro.es\/clientes\/saned\/Landing_BristolMyers_OK\/wp-content\/uploads\/2024\/12\/Logo-BMS-ok-1024x141.jpg 1024w, https:\/\/clientes2.smpro.es\/clientes\/saned\/Landing_BristolMyers_OK\/wp-content\/uploads\/2024\/12\/Logo-BMS-ok-300x41.jpg 300w, https:\/\/clientes2.smpro.es\/clientes\/saned\/Landing_BristolMyers_OK\/wp-content\/uploads\/2024\/12\/Logo-BMS-ok-768x106.jpg 768w, https:\/\/clientes2.smpro.es\/clientes\/saned\/Landing_BristolMyers_OK\/wp-content\/uploads\/2024\/12\/Logo-BMS-ok.jpg 1497w\" sizes=\"(max-width: 800px) 100vw, 800px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-ba0c49a elementor-widget elementor-widget-image\" data-id=\"ba0c49a\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"800\" height=\"419\" src=\"https:\/\/clientes2.smpro.es\/clientes\/saned\/Landing_BristolMyers_OK\/wp-content\/uploads\/2024\/12\/Medscape_Logo-1024x536.jpg\" class=\"attachment-large size-large wp-image-24\" alt=\"\" srcset=\"https:\/\/clientes2.smpro.es\/clientes\/saned\/Landing_BristolMyers_OK\/wp-content\/uploads\/2024\/12\/Medscape_Logo-1024x536.jpg 1024w, https:\/\/clientes2.smpro.es\/clientes\/saned\/Landing_BristolMyers_OK\/wp-content\/uploads\/2024\/12\/Medscape_Logo-300x157.jpg 300w, https:\/\/clientes2.smpro.es\/clientes\/saned\/Landing_BristolMyers_OK\/wp-content\/uploads\/2024\/12\/Medscape_Logo-768x402.jpg 768w, https:\/\/clientes2.smpro.es\/clientes\/saned\/Landing_BristolMyers_OK\/wp-content\/uploads\/2024\/12\/Medscape_Logo-1536x804.jpg 1536w, https:\/\/clientes2.smpro.es\/clientes\/saned\/Landing_BristolMyers_OK\/wp-content\/uploads\/2024\/12\/Medscape_Logo-2048x1073.jpg 2048w\" sizes=\"(max-width: 800px) 100vw, 800px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-042849f e-con-full e-flex e-con e-parent\" data-id=\"042849f\" data-element_type=\"container\">\n\t\t<div class=\"elementor-element elementor-element-102e56a e-con-full e-flex e-con e-child\" data-id=\"102e56a\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-4a61003 hfe-nav-menu__align-right elementor-widget-mobile__width-auto hfe-submenu-icon-arrow hfe-submenu-animation-none hfe-link-redirect-child hfe-nav-menu__breakpoint-tablet elementor-widget elementor-widget-navigation-menu\" data-id=\"4a61003\" data-element_type=\"widget\" data-settings=\"{&quot;padding_horizontal_menu_item&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:15,&quot;sizes&quot;:[]},&quot;padding_horizontal_menu_item_tablet&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;padding_horizontal_menu_item_mobile&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;padding_vertical_menu_item&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:15,&quot;sizes&quot;:[]},&quot;padding_vertical_menu_item_tablet&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;padding_vertical_menu_item_mobile&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;menu_space_between&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;menu_space_between_tablet&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;menu_space_between_mobile&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;menu_row_space&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;menu_row_space_tablet&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;menu_row_space_mobile&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;dropdown_border_radius&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true},&quot;dropdown_border_radius_tablet&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true},&quot;dropdown_border_radius_mobile&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true},&quot;width_dropdown_item&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;220&quot;,&quot;sizes&quot;:[]},&quot;width_dropdown_item_tablet&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;width_dropdown_item_mobile&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;padding_horizontal_dropdown_item&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;padding_horizontal_dropdown_item_tablet&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;padding_horizontal_dropdown_item_mobile&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;padding_vertical_dropdown_item&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:15,&quot;sizes&quot;:[]},&quot;padding_vertical_dropdown_item_tablet&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;padding_vertical_dropdown_item_mobile&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;distance_from_menu&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;distance_from_menu_tablet&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;distance_from_menu_mobile&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;toggle_size&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;toggle_size_tablet&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;toggle_size_mobile&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;toggle_border_width&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;toggle_border_width_tablet&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;toggle_border_width_mobile&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;toggle_border_radius&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;toggle_border_radius_tablet&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;toggle_border_radius_mobile&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]}}\" data-widget_type=\"navigation-menu.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t<div class=\"hfe-nav-menu hfe-layout-horizontal hfe-nav-menu-layout horizontal hfe-pointer__none\" data-layout=\"horizontal\">\n\t\t\t\t<div role=\"button\" class=\"hfe-nav-menu__toggle elementor-clickable\">\n\t\t\t\t\t<span class=\"screen-reader-text\">Men\u00fa<\/span>\n\t\t\t\t\t<div class=\"hfe-nav-menu-icon\">\n\t\t\t\t\t\t<svg aria-hidden=\"true\"  class=\"e-font-icon-svg e-fas-align-justify\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M432 416H16a16 16 0 0 0-16 16v32a16 16 0 0 0 16 16h416a16 16 0 0 0 16-16v-32a16 16 0 0 0-16-16zm0-128H16a16 16 0 0 0-16 16v32a16 16 0 0 0 16 16h416a16 16 0 0 0 16-16v-32a16 16 0 0 0-16-16zm0-128H16a16 16 0 0 0-16 16v32a16 16 0 0 0 16 16h416a16 16 0 0 0 16-16v-32a16 16 0 0 0-16-16zm0-128H16A16 16 0 0 0 0 48v32a16 16 0 0 0 16 16h416a16 16 0 0 0 16-16V48a16 16 0 0 0-16-16z\"><\/path><\/svg>\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<nav class=\"hfe-nav-menu__layout-horizontal hfe-nav-menu__submenu-arrow\" data-toggle-icon=\"&lt;svg aria-hidden=&quot;true&quot; tabindex=&quot;0&quot; class=&quot;e-font-icon-svg e-fas-align-justify&quot; viewBox=&quot;0 0 448 512&quot; xmlns=&quot;http:\/\/www.w3.org\/2000\/svg&quot;&gt;&lt;path d=&quot;M432 416H16a16 16 0 0 0-16 16v32a16 16 0 0 0 16 16h416a16 16 0 0 0 16-16v-32a16 16 0 0 0-16-16zm0-128H16a16 16 0 0 0-16 16v32a16 16 0 0 0 16 16h416a16 16 0 0 0 16-16v-32a16 16 0 0 0-16-16zm0-128H16a16 16 0 0 0-16 16v32a16 16 0 0 0 16 16h416a16 16 0 0 0 16-16v-32a16 16 0 0 0-16-16zm0-128H16A16 16 0 0 0 0 48v32a16 16 0 0 0 16 16h416a16 16 0 0 0 16-16V48a16 16 0 0 0-16-16z&quot;&gt;&lt;\/path&gt;&lt;\/svg&gt;\" data-close-icon=\"&lt;svg aria-hidden=&quot;true&quot; tabindex=&quot;0&quot; class=&quot;e-font-icon-svg e-far-window-close&quot; viewBox=&quot;0 0 512 512&quot; xmlns=&quot;http:\/\/www.w3.org\/2000\/svg&quot;&gt;&lt;path d=&quot;M464 32H48C21.5 32 0 53.5 0 80v352c0 26.5 21.5 48 48 48h416c26.5 0 48-21.5 48-48V80c0-26.5-21.5-48-48-48zm0 394c0 3.3-2.7 6-6 6H54c-3.3 0-6-2.7-6-6V86c0-3.3 2.7-6 6-6h404c3.3 0 6 2.7 6 6v340zM356.5 194.6L295.1 256l61.4 61.4c4.6 4.6 4.6 12.1 0 16.8l-22.3 22.3c-4.6 4.6-12.1 4.6-16.8 0L256 295.1l-61.4 61.4c-4.6 4.6-12.1 4.6-16.8 0l-22.3-22.3c-4.6-4.6-4.6-12.1 0-16.8l61.4-61.4-61.4-61.4c-4.6-4.6-4.6-12.1 0-16.8l22.3-22.3c4.6-4.6 12.1-4.6 16.8 0l61.4 61.4 61.4-61.4c4.6-4.6 12.1-4.6 16.8 0l22.3 22.3c4.7 4.6 4.7 12.1 0 16.8z&quot;&gt;&lt;\/path&gt;&lt;\/svg&gt;\" data-full-width=\"\">\n\t\t\t\t\t<ul id=\"menu-1-4a61003\" class=\"hfe-nav-menu\"><li id=\"menu-item-119\" class=\"menu-item menu-item-type-custom menu-item-object-custom menu-item-home parent hfe-creative-menu\"><a href=\"https:\/\/clientes2.smpro.es\/clientes\/saned\/Landing_BristolMyers_OK\/\" class = \"hfe-menu-item\">HOME<\/a><\/li>\n<li id=\"menu-item-120\" class=\"menu-item menu-item-type-custom menu-item-object-custom parent hfe-creative-menu\"><a href=\"https:\/\/clientes2.smpro.es\/clientes\/saned\/Landing_BristolMyers_OK\/landing-bristol-myers-articulos\/\" class = \"hfe-menu-item\">ARTIGOS<\/a><\/li>\n<li id=\"menu-item-121\" class=\"menu-item menu-item-type-custom menu-item-object-custom parent hfe-creative-menu\"><a href=\"https:\/\/clientes2.smpro.es\/clientes\/saned\/Landing_BristolMyers_OK\/landing-bristol-myers\/\" class = \"hfe-menu-item\">V\u00cdDEOS EDUCATIVOS<\/a><\/li>\n<li id=\"menu-item-122\" class=\"menu-item menu-item-type-custom menu-item-object-custom parent hfe-creative-menu\"><a href=\"https:\/\/clientes2.smpro.es\/clientes\/saned\/Landing_BristolMyers_OK\/landing-bristol-myers-videos-com-especialista\/\" class = \"hfe-menu-item\">V\u00cdDEOS COM ESPECIALISTA<\/a><\/li>\n<\/ul> \n\t\t\t\t<\/nav>\n\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-bea1e76 elementor-widget elementor-widget-heading\" data-id=\"bea1e76\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Deucravacitinibe: o primeiro inibidor de TYK2 traz resultados superiores e sustentados para Psor\u00edase em Placas<sup>1-5<\/sup><\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-696a54f elementor-widget elementor-widget-text-editor\" data-id=\"696a54f\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tEm estudos de fase III, o inibidor seletivo de TYK2, deucravacitinibe, demonstrou redu\u00e7\u00f5es significativas nos \u00edndices de gravidade da psor\u00edase em placas, oferecendo uma alternativa oral eficaz e bem tolerada para pacientes com formas moderadas a graves da doen\u00e7a.<sup>1-5<\/sup>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e59c450 elementor-widget elementor-widget-text-editor\" data-id=\"e59c450\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tA psor\u00edase em placas, forma mais prevalente de psor\u00edase, corresponde a aproximadamente <strong>80% dos casos diagnosticados<\/strong><sup>1<\/sup>. Trata-se de uma <strong>doen\u00e7a inflamat\u00f3ria imunomediada, cr\u00f4nica e sist\u00eamica<\/strong>, que se manifesta por les\u00f5es cut\u00e2neas bem delimitadas, avermelhadas e cobertas por escamas de apar\u00eancia prateada<sup>1<\/sup>. Essas les\u00f5es podem ser dolorosas e associar-se a prurido, <strong>comprometendo n\u00e3o apenas a integridade f\u00edsica, mas tamb\u00e9m o bem-estar psicol\u00f3gico dos pacientes<\/strong><sup>1<\/sup>. Os impactos incluem aumento do risco de depress\u00e3o, isolamento social e <strong>redu\u00e7\u00e3o da qualidade de vida<\/strong>, al\u00e9m de <strong>interferirem na produtividade e acarretarem custos significativos em sa\u00fade<\/strong><sup>1<\/sup>. Diante desse cen\u00e1rio, destaca-se a <strong>necessidade cont\u00ednua de terapias mais eficazes e seguras para o manejo da psor\u00edase em placas<\/strong><sup>1,2<\/sup>.<br><br>\n\nO desenvolvimento de novas terapias para a psor\u00edase em placas est\u00e1 intrinsecamente relacionado \u00e0 compreens\u00e3o de sua fisiopatologia<sup>1<\/sup>. Como uma doen\u00e7a imunomediada, ela \u00e9 caracterizada pela <strong>atua\u00e7\u00e3o de linf\u00f3citos T (Th17 e Tc17), que produzem interleucina 17 (IL-17) em resposta \u00e0 interleucina 23 (IL-23), liberada por c\u00e9lulas mononucleares d\u00e9rmicas. Esse eixo IL-23\/Th17 desempenha um papel central na perpetua\u00e7\u00e3o do processo inflamat\u00f3rio<\/strong>, tornando seus componentes alvos terap\u00eauticos promissores\u00b2. Atualmente, o tratamento para a psor\u00edase em placas baseia-se em <strong>medicamentos t\u00f3picos ou orais<\/strong> que, embora amplamente utilizados, apresentam <strong>efic\u00e1cia limitada e est\u00e3o frequentemente associados a toxicidades a longo prazo<\/strong>, especialmente no caso dos agentes orais<sup>1,2<\/sup>.<br><br>\n\nNesse contexto, as vias intracelulares associadas \u00e0 resposta imunol\u00f3gica \u00e0 IL-23 destacam a tirosina quinase 2 (TYK2) como um mediador essencial no processo inflamat\u00f3rio da psor\u00edase em placas<sup>2<\/sup>. <strong>A TYK2, ao dimerizar com a JAK2, desempenha um papel central na transdu\u00e7\u00e3o do sinal intracelular da IL-23<\/strong>, promovendo a <strong>expans\u00e3o e a sobreviv\u00eancia das c\u00e9lulas Th17<\/strong>. <strong>As citocinas produzidas por essas popula\u00e7\u00f5es atuam sinergicamente para amplificar a prolifera\u00e7\u00e3o de queratin\u00f3citos e intensificar os processos de ativa\u00e7\u00e3o celular<\/strong>, caracter\u00edsticos da psor\u00edase<sup>2<\/sup>. Adicionalmente, estudos demonstram que indiv\u00edduos com polimorfismos gen\u00e9ticos associados \u00e0 <strong>perda de fun\u00e7\u00e3o do gene TYK2 apresentam menor risco de desenvolver psor\u00edase e outras doen\u00e7as imunomediadas<\/strong>. Esse achado refor\u00e7a o papel central da TYK2 na fisiopatologia dessas condi\u00e7\u00f5es, tornando sua inibi\u00e7\u00e3o uma abordagem terap\u00eautica promissora para o tratamento da psor\u00edase<sup>2<\/sup>.<br><br>\n\nO <strong>deucravacitinibe surge como um f\u00e1rmaco oral inovador, atuando como um inibidor altamente seletivo de TYK2 por meio de um mecanismo alost\u00e9rico<\/strong><sup>1,2<\/sup>. Sua principal caracter\u00edstica \u00e9 a seletividade, uma vez que estudos demonstraram que o <strong>deucravacitinibe apresenta m\u00ednima ou nenhuma atividade sobre as demais JAKs, reduzindo o risco de interfer\u00eancia em fun\u00e7\u00f5es fisiol\u00f3gicas mediadas por essas quinases<\/strong><sup>2<\/sup>.<br><br>\n\nDois importantes estudos cl\u00ednicos de fase III<strong>, POETYK PSO-1 e PSO-2, avaliaram a efic\u00e1cia e seguran\u00e7a do deucravacitinibe<\/strong><sup>2<\/sup>. O estudo PSO-1 comparou a efic\u00e1cia e seguran\u00e7a do inibidor de TYK2 (n=332; 6mg\/dia) com placebo (n=166) e apremilast (n=168; 30mg duas vezes ao dia) em pacientes com <strong>psor\u00edase em placas moderada a grave<\/strong><sup>2<\/sup>. O apremilaste trata-se de um comparador ativo, por se tratar de um inibidor oral da fosfodiesterase 4 (PDE4), sendo considerado at\u00e9 ent\u00e3o o padr\u00e3o de tratamento oral nos Estados Unidos da Am\u00e9rica<sup>3<\/sup>.<br><br>\n\nComo endpoint prim\u00e1rios, o estudo avaliou duas vari\u00e1veis: <strong>PASI 75 e sPGA 0\/1<\/strong>. O PASI 75 mensura uma redu\u00e7\u00e3o de 75% ou mais na \u00e1rea de psor\u00edase, enquanto o sPGA 0\/1 avalia a gravidade da doen\u00e7a, considerando os escores de avalia\u00e7\u00e3o global do m\u00e9dico em compara\u00e7\u00e3o com o baseline. A efic\u00e1cia foi definida como uma melhora de 2 pontos na semana 16 em rela\u00e7\u00e3o ao valor inicial para o deucravacitinibe<sup>2,4<\/sup>.<br><br>\n\n<strong>As taxas de resposta para ambas as m\u00e9tricas foram significativamente superiores no grupo deucravacitinibe em compara\u00e7\u00e3o ao placebo<\/strong>, com um <strong>PASI 75 de 58,4%<\/strong> versus 12,7% (p&lt;0,0001) e sPGA 0\/1 de 53,6% versus 7,2% (p&lt;0,0001) na semana 16<sup>2<\/sup>. <strong>As respostas continuaram a melhorar at\u00e9 a <\/strong><strong>semana 24, onde observou-se um pico de efic\u00e1cia, com as m\u00e9tricas\u00a0 sustentando essa boa performance do deucravacitinibe, como por exemplo um um PASI 75 de 69,3% versus 38,1% do apremilast e um PASI 90 de 42,2% versus 22%<\/strong><sup>2<\/sup>. A efic\u00e1cia do inibidor de TYK2 foi sustentada at\u00e9 a semana 52 de tratamento cont\u00ednuo<sup>2,4<\/sup>.<br><br>\n\nAl\u00e9m da efic\u00e1cia j\u00e1 demonstrada, <strong>o estudo PSO-2, com delineamento semelhante ao PSO-1, teve como objetivo confirmar a superioridade do deucravacitinibe em 16 semanas<\/strong>, utilizando as mesmas m\u00e9tricas<sup>4<\/sup>. <strong>Na 16\u00aa semana, 53% dos pacientes tratados com decravacitinibe alcan\u00e7aram uma redu\u00e7\u00e3o de 75% ou mais no PASI<\/strong>, em compara\u00e7\u00e3o com 9,4% no grupo placebo e 39,8% no grupo apremilaste. Quando observada a <strong>24\u00aa semana, o f\u00e1rmaco de interesse sustentou a efic\u00e1cia, de modo que as taxas de resposta foram superiores para todas as m\u00e9tricas avaliadas, com destaque para o PASI 90 de 32,5%<\/strong> comparado a 19,7% no bra\u00e7o apremilast (p=0,0001)<sup>4<\/sup>. Os resultados do sPGA tamb\u00e9m seguiram o mesmo padr\u00e3o favor\u00e1vel ao inibidor de TYK2, refor\u00e7ando seu perfil positivo como tratamento oral<sup>4<\/sup>.<br><br>\n\nCom rela\u00e7\u00e3o ao perfil de seguran\u00e7a, <strong>eventos adversos graves ou descontinua\u00e7\u00e3o devido a esse desfecho foram infrequentes, sendo o evento adverso mais comum os quadros de nasofaringite (10,8%)<\/strong><sup>5<\/sup>.<br><br>\n\nMais recentemente, no 33rd European Academy of Dermatology &amp; Venereology (EADV), Diamant Tha\u00e7i e demais investigadores apresentaram dados de resposta em 4 anos que incluem a avalia\u00e7\u00e3o de pacientes dos estudos acima descritos e que ap\u00f3s a 52\u00aa semana, poderiam ser inclu\u00eddos no estudo POETYK LTE para receber deucravacitinibe open-label<sup>6<\/sup>. Dentre os resultados discutidos, destacou-se a efic\u00e1cia sustentada de <strong>deucravacitinibe em \u00e1reas de dif\u00edcil tratamento como couro cabelo (ss-PGA), unhas e palmoplantar(PGA-F), onde essas respostas de ss-PGA 0\/1 e ss-PGA 0, bem como as de PGA-F 0\/1 e PGA-F 0 foram mantidas ou melhoradas\/mantidas, respectivamente, da semana 52 \u00e0 semana 196, demonstrando resposta duradoura mesmo em regi\u00f5es classicamente de dif\u00edcil manejo cl\u00ednico<sup>6<\/sup>.<\/strong><br><br>\n\nEm conclus\u00e3o, a inibi\u00e7\u00e3o altamente seletiva de TYK2, utilizando o deucravacitinibe, demonstrou ser uma op\u00e7\u00e3o terap\u00eautica promissora para pacientes com psor\u00edase em placas moderada a grave, com efic\u00e1cia superior ao placebo e ao apremilast, evidenciada por redu\u00e7\u00f5es significativas no PASI 75 e no sPGA<sup>2,4<\/sup>. Os estudos PSO-1 e PSO-2 confirmaram a superioridade do deucravacitinibe em 16 semanas e com resposta sustentada<sup>2,4<\/sup>. Al\u00e9m disso, seu perfil de seguran\u00e7a foi favor\u00e1vel, com baixa incid\u00eancia de eventos adversos graves, destacando a nasofaringite como a toxicidade mais comum<sup>2,4,5<\/sup>. Em suas an\u00e1lises de efic\u00e1cia em 4 anos (POETYK LTE), o f\u00e1rmaco demonstrou sustentabilidade de resposta e a\u00e7\u00e3o terap\u00eautica mesmo em \u00e1reas de dif\u00edcil tratamento<sup>2,4-6<\/sup>.<br><br>\n\n<strong>Refer\u00eancias:<\/strong>\n<ol>\n \t<li>Strychalski ML, Brown HS, Bishop SC. Cytokine Modulators in Plaque Psoriasis\u00a0&#8211;\u00a0A Review of Current and Prospective Biologic Therapeutic Approaches. JAAD Int. 2022.<\/li>\n \t<li>Krueger JG, McInnes IB, Blauvelt A. Tyrosine kinase 2 and Janus kinase\u2012signal transducer and activator of transcription signaling and inhibition in plaque psoriasis. J Am Acad Dermatol. 2022.<\/li>\n \t<li>Park SH, Lambton M, Schmier J, Hovland S, Wittstock K, Patel V. Cost per response analysis of deucravacitinib versus apremilast and first-line biologics among patients with moderate to severe plaque psoriasis in the United States. J Dermatolog Treat. 2024;35(1):2366503. doi:10.1080\/09546634.2024.2366503.<\/li>\n \t<li>Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023.<\/li>\n \t<li>Strober B, Tha\u00e7i D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr\u00a0Evaluation of\u00a0TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023.<\/li>\n \t<li>Tha\u00e7i D, Warren RB, Langley R, et al. Deucravacitinib efficacy in patients with moderate to severe psoriasis with scalp and fingernail disease: response over 4 years of treatment in the phase 3 POETYK PSO-1, PSO-2, and LTE trials. 33rd European Academy of Dermatology &amp; Venereology (EADV).<\/li>\n<\/ol>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-bbb6e1e elementor-widget elementor-widget-text-editor\" data-id=\"bbb6e1e\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>ID IMM-BR-2400080 \u2013 Dezembro\/2024 &#8211; Material n\u00e3o promocional destinado a profissionais da \u00e1rea da sa\u00fade.<\/p><p>All material on this website is protected by copyright, Copyright \u00a9 1994-2023 by WebMD LLC. This website also contains material copyrighted by 3rd parties.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-d88ef10 e-flex e-con-boxed e-con e-parent\" data-id=\"d88ef10\" data-element_type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-3b997cc elementor-widget elementor-widget-button\" data-id=\"3b997cc\" data-element_type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/www.medscape.com\/public\/privacy\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Privacy Policy<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Men\u00fa HOME ARTIGOS V\u00cdDEOS EDUCATIVOS V\u00cdDEOS COM ESPECIALISTA Deucravacitinibe: o primeiro inibidor de TYK2 traz resultados superiores e sustentados para Psor\u00edase em Placas1-5 Em estudos de fase III, o inibidor seletivo de TYK2, deucravacitinibe, demonstrou redu\u00e7\u00f5es significativas nos \u00edndices de gravidade da psor\u00edase em placas, oferecendo uma alternativa oral eficaz e bem tolerada para pacientes [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"footnotes":""},"class_list":["post-64","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/clientes2.smpro.es\/clientes\/saned\/Landing_BristolMyers_OK\/wp-json\/wp\/v2\/pages\/64","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clientes2.smpro.es\/clientes\/saned\/Landing_BristolMyers_OK\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/clientes2.smpro.es\/clientes\/saned\/Landing_BristolMyers_OK\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/clientes2.smpro.es\/clientes\/saned\/Landing_BristolMyers_OK\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/clientes2.smpro.es\/clientes\/saned\/Landing_BristolMyers_OK\/wp-json\/wp\/v2\/comments?post=64"}],"version-history":[{"count":16,"href":"https:\/\/clientes2.smpro.es\/clientes\/saned\/Landing_BristolMyers_OK\/wp-json\/wp\/v2\/pages\/64\/revisions"}],"predecessor-version":[{"id":193,"href":"https:\/\/clientes2.smpro.es\/clientes\/saned\/Landing_BristolMyers_OK\/wp-json\/wp\/v2\/pages\/64\/revisions\/193"}],"wp:attachment":[{"href":"https:\/\/clientes2.smpro.es\/clientes\/saned\/Landing_BristolMyers_OK\/wp-json\/wp\/v2\/media?parent=64"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}